Vardenafil - PDE5 inhibitor number 3

International Journal of Clinical Practice

Volumn 58, Issue 3, 2004, Pages 229-

  Jackson, Graham ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RHINITIS; SEXUAL INTERCOURSE; SIDE EFFECT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 2342421979     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00190.x     Document Type: Editorial

References (7)

1. Jackson G. Sex, the heart and erectile dysfunction. Taylor & Francis, 2004.
2. Lue T.F. Erectile Dysfunction. N Engl J Med 2000; 342: 1802-13.
3. Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003; 108: 239-44.
4. Goldstein I, Young JM, Fischer J et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. Diabetes Care 2003; 26: 777-83.
5. Brock G, Nehra A, Lipshultz LI et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278-83.
6. Porst H, Young JM, Schmidt AC et al. Efficacy and tolerability of vardenafil for treatment of erectile dysfuction in patient subgroups. Urology 2003; 62: 519-24.
7. Stief C, Porst H, Saenz de Tejada I et al. Sustained efficacy and tolerability with vardenafil over two years of treatment in men with erectile dysfunction. Int J Clin Pract 2004; 58: 230-39.